An overview of salsalate as a potential antidiabetic therapy

Drugs of Today

Volumn 46, Issue 11, 2010, Pages 847-853

  Desouza, Cyrus ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; FATTY ACID; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; SALSALATE; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; DRUG ABSORPTION; DRUG ACETYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; HEARTBURN; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPOLYSIS; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TINNITUS; TREATMENT INDICATION; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; NF-KAPPA B; SALICYLIC ACIDS;

EID: 79955811003     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.11.1534820     Document Type: Review

References (44)

1. Stern, N., Izkhakov, Y. The metabolic syndrome revisited: "cardiometabolic risk" emerges as common ground between differing views of the ADA and AHA. J Cardiometab Syndr 2006, 1(5): 362-3.
2. Hong, Y., Jin, X., Mo, J. et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality - Results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007, 262(1): 113-22.
3. Sjoholm, A., Nystrom, T. Endothelial inflammation in insulin resistance. Lancet 2005, 365(9459): 610-2.
4. Smith, U. Symposium on diabetes, Inflammation and cardiovascular disease. J Intern Med 2007, 262(2): 142-4.
5. Ndumele, C.E., Pradhan, A.D., Ridker, P.M. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 2006, 1(3): 190-6.
6. Shoelson, S.E., Herrero, L., Naaz, A. Obesity, inflammation and insulin resistance. Gastroenterology 2007, 132(6): 2169-80.
7. Williamson, R. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901, 1(2100): 760-2.
8. Hundal, R.S., Petersen, K.F., Mayerson, A.B., Randhawa, P.S., Inzucchi, S., Shoelson, S.E., Shulman, G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109(10): 1321-6.
9. Goldfine, A.B., Fonseca, V., Jablonski, K.A., Pyle, L., Staten, M.A., Shoelson, S.E. The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. Ann Intern Med 2010, 152(6): 346-57.
10. Goldfine, A.B., Silver, R., Aldhahi, W., Cai, D., Tatro, E., Lee, J., Shoelson, S.E. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transi Sci 2008, 1(1): 36-43.
11. Fleischman, A., Shoelson, S.E., Bernier, R., Goldfine, A.B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31(2): 289-94.
12. Sheldon, G.G., Rupp, J.J. The long-term response of diabetes mellitus to salicylate therapy. JAMA 1962, 180(1): 65-6.
13. Chen, M., Robertson, R.P. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes 1978, 27(7): 750-6.
14. Park, E., Wong, V., Guan, X., Oprescu, A.I., Giacca, A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol 2007, 195(2): 323-31.
15. Xiao, C., Giacca, A., Lewis, G.F. The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty-acid induced insulin resistance and β-cell dysfunction in overweight and obese nondiabetic men. Am J Physiol Endocrinol Metab 2009, Epub ahead of print.
16. Koska, J., Ortega, E., Bunt, J.C. et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: Results of a randomised double-blind placebo-controlled study. Diabetologia 2009, 52(3): 385-93.
17. De Taeye, B., Novitskaya, T., McGuinness, O.P., Gleaves, L., Medda, M., Covington, J.W., Vaughan, D.E. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 2007, 293(3): E713-25.
18. Popa, C., Netea, M.G., van Riel, P.L., van der Meer, J.W., Stalenhoef, A.F. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007, 48(4): 751-62.
19. Erol, A. Insulin resistance is an evolutionary conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 2007, 29(8): 811-8.
20. Morisco, C., Marrone, C., Trimarco, V., Crispo, S., Monti, M.G., Sadoshima, J., Trimarco, B. Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res 2007, 76(3): 453-64.
21. Kaneto, H., Nakatani, Y., Kawamori, D., Miyatsuka, T., Matsuoka, T.A. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud 2004, 1(4): 165-74.
22. Liuwantara, D., Elliot, M., Smith, M.W. et al. Nuclear factor-kappaB regulates beta-cell death: A critical role for A20 in beta-cell protection. Diabetes 2006, 55(9): 2491-501.
23. Schiekofer, S., Galasso, G., Andrassy, M., Aprahamian, T., Schneider, J., Rocnik, E. Glucose control with insulin results in reduction of NF-kappaB-binding activity in mononuclear blood cells of patients with recently manifested type 1 diabetes. Diabetes Obes Metab 2006, 8(5): 473-82.
24. Li, G., Barrett, E.J., Barrett, M.O., Cao, W., Liu, Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 2007, 148(7): 3356-63.
25. Ursini, F., Succurro, E., Grembiales A., Rudi, S., Grembiale, R.D., Arturi, F. Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. Int J Immunopathol Pharmacol 2010, 23(3): 961-3.
26. Huvers, F.C., Popa, C., Netea, M.G., van den Hoogen, F.H., Tack, C.J. Improved insulin sensitivity by anti-TNFa antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007, 66(4): 558-9.
27. Sauter, N.S., Schulthess, F.T., Galasso, R., Castellani, L.W., Maedler, K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008, 149(5): 2208-18.
28. Fearon, W.F., Fearon, D.T. Inflammation and cardiovascular disease: Role of the interleukin-1 receptor antagonist. Circulation 2008, 117(20): 2577-9.
29. Goldberg, R. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94(9): 3171-82.
30. Zu, L., Jiang, H., He, J., Xu, C., Pu, S., Liu, M., Xu, G. Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes. Mol Pharmacol 2008, 73(1): 215-23.
31. Schonhofer, P.S., Sohn, J., Peters, H.D., Dinnendahl, V. Effects of sodium salicylate and acetylsalicylic acid on the lipolytic system of fat cells. Biochem Pharmacol 1973, 22(5): 629-37.
32. Frantz, B., O'Neill, E.A. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995, 270(5244): 2017-9.
33. Jurivich, D.A., Pachetti, C., Qiu, L., Welk, J.F. Salicylate triggers heat shock factor differently than heat. J Biol Chem 1995, 270(41): 24489-95.
34. Faivre, J., Faivre, M., Lery, N., Ducluzeau, R., Moulinier, B., Paliard, P. Aspirin and gastrointestinal bleeding. Interest of plasma salicylate determination. Digestion 1979, 19(3): 218-20.
35. Morris, H.G., Sherman, N.A., McQuain, C., Goldlust, M.B., Chang, S.F., Harrison, L.I. Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans. Ther Drug Monit 9185, 7(4): 435-8.
36. Hileman, C.O., Carman, T.L., Gripshover, B.M. et al. Salsalate is poorly tolerated and falls to improve endothelial function in virologically suppressed HIV-infected adults. AIDS 2010, 24(12): 1958-61.
37. Phillips, B.B., Joss, J.D., Mulhausen, P.L. Blood pressure elevation in a patient treated with salsalate. Ann Pharmacother 2002, 36(4): 624-7.
38. Stillman, M.T., Schlesinger, P.A. Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned? Arch Intern Med 1990, 150(2): 268-70.
39. Abraham, P.A., Stillman, M.T. Salsalate exacerbation of chronic renal insufficiency. Relation to inhibition of prostaglandin synthesis. Arch Intern Med 1987, 147(9): 1674-6.
40. Pierce, G.L., Lesniewski, L.A., Lawson, B.R., Beske, S.D., Seals, D.R. Nuclear factor-kappaB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009, 119(9): 1284-92.
41. Gupta, S.K., Johnson, R.M., Saha, C. et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study. AIDS 2008, 22(5): 653-5.
42. Nissen, S.E., Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24): 2457-71
43. Erdmann, E., Dormandy, J., Wilcox, R., Massi-Benedetti, M., Charbonnel, B. PROactive 07: Pioglitazone in the treatment of type 2 diabetes: Results of the PROactive study. Vasc Health Risk Manag 2007, 3(4): 355-70.
44. Desouza, C., Rentschler, L., Fonseca, V. Peroxisome proliferator- activated receptors as stimulants of angiogenesis. Diabetes Metab Syndr Obes 2009, 2: 165-72.